hotspot -WSS

hotspot

author：fashion 2025-09-07 13:57:46 - browse：78

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Venture capitalist Bob Kocher on the state of digital health

explore

entertainment

WSS

Syphilis numbers in the United States reach record heights

Medicare drug price negotiation legal challenge met with skepticism

How generative AI ratchets up security threats for health systems

Solving academic medical centers' existential crisis

Arc Institute generative AI designs new CRISPR systems

Merck CEO won’t testify in Senate, citing no expertise in drug prices

leisure time

hotspot

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Arc Institute generative AI designs new CRISPR systems

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout LOUD podcast: Live from STAT Breakthrough Summit West

The cancer drug shortage isn’t new — and neither are the solutions

Addiction experts warn against a second 'war on drugs'

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

hotspot

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Pancreatic cancer early detection could be helped by AI

FTC sues over Novant Health acquisition of two N.C. hospitals

It's time to retire 'poor historian' from clinicians' vocabularies

Biogen walks away from Aduhelm, years after polarizing approval

Vertex non

explore

explore

entertainment

focus